EUVIMEDEUVIMED entdecken
Crossref

Improved high‐performance liquid chromatography tandem mass spectrometry method for quantification of infliximab in pediatric plasma and its application in therapeutic drug monitoring

Boran Yu, Siyao Jin, Jiaqi Han, Xiaona Li, Jiamin Xu, Ning Sun, Liang Sun, Xiaoling Wang, Libo Zhao iD

Rapid Communications in Mass Spectrometry · 2024

DOI: 10.1002/rcm.9865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2024. Verfasst von Boran Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Infliximab, Drug Monitoring, Tandem Mass Spectrometry. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Beijing Municipal Natural Science Foundation, Key Clinical Projects of Peking University Third Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

The application of infliximab (IFX) to immune‐mediated disease is limited by the significant individual variability and associated clinical nonresponse, emphasizing the importance of therapeutic drug monitoring (TDM). Because of the cross‐reactivity, limited linear range, and high costs, the clinical application of the previous reported methods was limited. Here, an improved high‐performance liquid chromatography tandem mass spectrometry (HPLC‐MS/MS) method was developed to address the issues.

Methods

This study developed an improved bioanalytical HPLC‐MS/MS method coupling nanosurface and molecular‐orientation limited proteolysis technology. The commercially available compound P14R was selected as the internal standard. This method was developed with fewer volume of reagents and was thoroughly validated. The validated method was applied to TDM in pediatric inflammatory bowel disease (IBD).

Results

Chromatography was performed using a Shim‐pack GISS‐HP C 18 metal‐free column (3 μm, 2.1 × 100 mm) with a gradient elution of 0.1% formic acid in water and acetonitrile at 0.4 mL/min. Detection and quantitation were performed using electrospray ionization (ESI) and multiple reaction monitoring in the positive ion mode. The method was validated to demonstrate its selectivity, linearity, accuracy, precision, recovery, matrix effect, and stability. The method exhibited a linear dynamic range of 0.3–100 μg/mL, with intra‐ and inter‐day precision and relative errors below 15%. The recovery and matrix effect were measured as 87.28%–89.72% and 41.98%–67.17%, respectively, which were effectively compensated by the internal standard. A total of 32 samples collected from 24 pediatric patients with IBD were analyzed using the validated method, and only 46.9% achieved the reported targeted trough level.

Conclusion

This study developed an improved HPLC‐MS/MS method for the quantitative determination of IFX concentration in human plasma. The accurate, reliable, and cost‐effective method was validated and utilized in the analysis of clinical samples. The results confirmed the importance of TDM on IFX and the clinical application prospects of the improved method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabDrug MonitoringTandem Mass SpectrometryHumansChromatography, High Pressure LiquidChildInflammatory Bowel DiseasesReproducibility of ResultsLimit of DetectionAdolescentLinear ModelsMale

Substanzen

Infliximab

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Shimadzu (China) Co., Beijing, China.

ORCID-Profile: Libo Zhao

Förderung

  • Beijing Municipal Natural Science Foundation
  • Key Clinical Projects of Peking University Third Hospital

Zitieren

APA

Yu, B., Jin, S., Han, J., Li, X., Xu, J., Sun, N., Sun, L., Wang, X., & Zhao, L. (2024). Improved high‐performance liquid chromatography tandem mass spectrometry method for quantification of infliximab in pediatric plasma and its application in therapeutic drug monitoring. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.9865

Vancouver

Yu B, Jin S, Han J, Li X, Xu J, Sun N, et al. Improved high‐performance liquid chromatography tandem mass spectrometry method for quantification of infliximab in pediatric plasma and its application in therapeutic drug monitoring. Rapid Communications in Mass Spectrometry. 2024. doi:10.1002/rcm.9865

BibTeX
@article{Yu2024,
  author = {Yu, Boran and Jin, Siyao and Han, Jiaqi and Li, Xiaona and Xu, Jiamin and Sun, Ning and Sun, Liang and Wang, Xiaoling and Zhao, Libo},
  title = {Improved high‐performance liquid chromatography tandem mass spectrometry method for quantification of infliximab in pediatric plasma and its application in therapeutic drug monitoring},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2024},
  doi = {10.1002/rcm.9865}
}
Kostenlos starten →